Recently, Shenzhen Chipscreen Biosciences Co., Ltd. (A-share stock code: 688321; hereinafter referred to as "Chipscreen Biosciences") successfully completed its private placement of A-shares to specific objects (the "Issuance"), raising nearly RMB 950 million in net proceeds. Llinks, acting as the issuer's counsel, provided comprehensive legal services throughout the process.
Chipscreen Biosciences is an innovative drug enterprise driven by core technologies and dedicated to building a globally competitive product pipeline. As a pioneer in China's original drug sector, the company adheres to the philosophy of "Original, Safe, Effective, and China-rooted," striving to provide patients with revolutionary, innovative mechanism-based drugs for urgent clinical needs. The company has established a complete industrial chain layout ranging from early-stage exploratory discovery to commercialization, delivering original Chinese medicines to patients worldwide.
The proceeds from this Issuance are primarily intended for the "Innovative Drug R&D Project" and the "Pengzhou Chipscreen Original New Drug Manufacturing Base (Phase I) Project." These investments will accelerate the clinical progress and industrialization of the company's core R&D pipeline while further enhancing its independent R&D and large-scale production capabilities for original new drugs.
Following its previous roles in assisting Chipscreen Biosciences with its STAR Market IPO and convertible bond issuance, Llinks has once again provided a full range of professional legal services for this A-share private placement.
